輸血診断の世界市場：市場規模（コンポーネント別・用途別・エンドユーザー別・地域別）、将来予測

輸血診断の市場規模と予測

輸血診断の市場規模は、2024年に56億4,000万米ドルと評価され、2026年から2032年にかけてCAGR 7.86%で成長し、2032年には103億3,000万米ドルに達すると予測されます。

輸血診断には、輸血の安全性と適合性を保証するために設計されたいくつかの重要な検査と手順が含まれます。これらの検査は、ドナー血液型とレシピエント血液型の最適な適合を判定するのに役立ち、致命的な輸血反応の危険性を低減します。重要な検査は、ABOとRhの血液型を特定する血液型検査と、ドナーとレシピエントの血液の適合性を確認するクロスマッチングです。

これらの診断は、輸血の安全性と有効性を保証するために不可欠であり、特に血液型検査、クロスマッチング、感染症検査が重要です。血液型検査は、ドナーとレシピエントの血液型（ABOとRh）を特定し、輸血関連合併症を予防するために不可欠です。クロスマッチング検査は、ドナーとレシピエントの血液の適合性を高め、問題が起こる可能性を低くします。

輸血診断の将来的な用途は、技術的進歩とともに進化し、検査速度、精度、安全性が向上すると予測されます。核酸検査（NAT）のような分子診断法は、より低用量で病原体の早期検出を可能にし、輸血の安全性を向上させるとして人気を集めています。

世界の輸血診断の市場力学

世界の輸血診断市場を形成している主な市場力学は以下の通りである：

主な市場促進要因

輸血需要の増加：主な要因の一つは、慢性疾患、外傷、手術、緊急治療が一般的になるにつれて輸血の必要性が高まることです。がん、心血管疾患、貧血などの疾患では、輸血を繰り返す必要があることが多く、血液の安全性と適合性を確保するための包括的な診断技術の必要性が高まっています。

技術の進歩：診断技術の革新が市場拡大の原動力となっています。自動化技術、核酸検査（NAT）、次世代シーケンシングの使用により、血液検査の精度、スピード、信頼性が向上しています。これらの開発により、人為的ミスが減少し、血液媒介性疾患の検出が改善され、血液適合検査の結果が改善された結果、高度な診断機器に対する需要が増加しています。

厳しい安全規制：政府および保健機関は、溶血反応や感染症の蔓延といった輸血関連の結果を減らすために、厳格な安全要件を課しています。これらの要件は、献血された血液の完全なスクリーニングを必要とするため、試薬、装置、ソフトウェアなどの最新の診断機器を使用し、コンプライアンスを確保する必要があります。

主な課題

厳しい規制要件：輸血診断は、FDA、EMA、その他の国際規制機関などの保健当局による厳しい規制要件の対象です。これらの規制は、製品の承認や市場導入を遅らせる可能性のある大規模な臨床試験や安全性の検証を必要とします。

診断機器のコスト：高度な診断機器、特に分子診断や核酸検査などの最先端技術を搭載した機器は、法外に高価な場合があります。特に中低所得国の小規模な医療施設では、こうした費用は法外なものとなる可能性があります。これらの技術や、頻繁に使用するために必要な試薬の価格は、その普及を制限し、資源に制約のある場所でのアクセスの障害となっています。

血液供給不足：輸血診断の有効性は、安全で適合性のある血液供給が可能であることが条件となります。しかし、ドナー不足による血液不足や、血液の採取・保管における物流上の課題は、診断プロセスを危険にさらす可能性があります。

主な動向

技術進歩：自動分析装置や分子診断などの高度な技術の導入は、輸血診断に変化をもたらしています。自動化されたソリューションは、血液型判定や病原体検出のスピードと精度を高め、人為的ミスを減らし、ラボのワークフロー効率を向上させます。

血液成分の需要拡大：慢性疾患、外科手術、外傷が一般的になるにつれ、輸血の需要も世界中で増加しています。この動向は、安全で適合性の高い血液製剤を保証するための効果的な輸血診断の必要性を強調しています。医療専門家は、輸血を必要とする患者数の増加に対応するため、包括的な検査基準にますます注目しています。

規制遵守と安全基準：規制機関は、輸血処置の安全性と有効性を保証するため、より強力な規則を実施しています。これらの要件は包括的な診断検査を必要とするため、高品質の試薬、キット、機器に対する需要が高まっています。コンプライアンス要件がますます厳しくなる中、医療施設はこれらの安全基準を達成するために信頼性の高い診断ソリューションに投資しています。

目次

第1章 世界の輸血診断市場：イントロダクション

• 市場概要
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の輸血診断市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の輸血診断市場：コンポーネント別

• 概要
• 試薬・キット
• 機器
• ソフトウェア・サービス

第6章 世界の輸血診断市場：用途別

• 概要
• 血液型分類
• 疾患スクリーニング

第7章 世界の輸血診断市場：エンドユーザー別

• 血液バンク
• 病院
• 診断研究所

第8章 世界の輸血診断市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の輸血診断市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Ortho clinical Diagnostics
• DiaSorin S.p. A
• Abbott
• Grifols
• S.A., F.
• Hoffmann-La Roche Ltd
• Bio-Rad Laboratories
• Siemens Healthcare Private Limited
• Thermo Fisher Scientific Inc.
• Beckman Coulter, Inc

第11章 付録

• 関連分析

Blood Transfusion Diagnostics Market Size and Forecast

Blood Transfusion Diagnostics Market size was valued at USD 5.64 Billion in 2024 and is projected to reach USD 10.33 Billion by 2032, growing at a CAGR of 7.86% from 2026 to 2032.

Blood transfusion diagnostics include several key tests and procedures designed to assure the safety and compatibility of blood transfusions. These tests assist in determining the optimal match between donor and recipient blood types reducing the danger of potentially fatal transfusion reactions. The key tests are blood typing which identifies ABO and Rh blood groups and cross-matching which confirms compatibility between the donor's and recipient's blood.

These diagnostics are critical for guaranteeing the safety and efficacy of blood transfusions, particularly blood typing, cross-matching, and infectious disease testing. Blood typing is essential for identifying the donor and recipient's blood groups (ABO and Rh) and preventing transfusion-related complications. Cross-matching tests ensure greater compatibility between donor and recipient blood lowering the likelihood of problems.

The future usage of blood transfusion diagnostics is projected to evolve in tandem with technological advancements, improving testing speed, accuracy, and safety. Molecular diagnostics, such as nucleic acid testing (NAT), are gaining popularity allowing for earlier detection of pathogens at lower doses, hence enhancing transfusion safety.

Global Blood Transfusion Diagnostics Market Dynamics

The key market dynamics that are shaping the global blood transfusion diagnostics market include:

Key Market Drivers:

Rising Blood Transfusion Demand: One of the key factors is the increased need for blood transfusions as chronic diseases, trauma cases, surgeries, and emergency treatment become more common. Conditions such as cancer, cardiovascular disease, and anemia frequently necessitate repeated transfusions increasing the necessity for comprehensive diagnostic technologies to ensure blood safety and compatibility.

Technological Advancements: Innovations in diagnostic technology are driving market expansion. The use of automated technologies, nucleic acid testing (NAT), and next-generation sequencing has improved the accuracy, speed, and reliability of blood tests. These developments reduce human error, improve the detection of blood-borne diseases, and provide improved results in blood compatibility testing resulting in increased demand for advanced diagnostic instruments.

Stringent Safety Regulations: Governments and health organizations impose stringent safety requirements to reduce transfusion-related consequences such as hemolytic responses and the spread of infectious infections. These requirements require complete screening of donated blood necessitating the use of modern diagnostics such as reagents, devices, and software, to ensure compliance.

Key Challenges:

Stringent Regulatory Requirements: Blood transfusion diagnostics are subject to stringent regulatory requirements from health authorities such as the FDA, EMA, and other international regulatory bodies. These rules necessitate significant clinical investigations and safety validations which might delay product approval and market introduction.

Diagnostic Tool Costs: Advanced diagnostic equipment, particularly devices equipped with cutting-edge technology such as molecular diagnostics and nucleic acid testing can be prohibitively expensive. These expenses can be prohibitive for smaller healthcare facilities, especially in low- and middle-income nations. The price of these technologies and the reagents necessary for frequent use limits their widespread acceptance presenting barriers to access in resource-constrained places.

Blood Supply Shortages: The efficacy of blood transfusion diagnostics is contingent on the availability of safe and compatible blood supplies. However, blood shortages caused by insufficient donors or logistical challenges during collection and storage can risk the diagnostic process.

Key Trends:

Technological Advancements: The incorporation of sophisticated technology such as automated analyzers and molecular diagnostics is altering blood transfusion diagnosis. Automated solutions increase the speed and accuracy of blood typing and pathogen detection, lowering human error and increasing lab workflow efficiency.

Growing Demand for Blood Components: As chronic diseases, surgical operations, and trauma cases become more common, so does the demand for blood transfusions around the world. This trend emphasizes the need for effective blood transfusion diagnostics to assure safe and compatible blood products. Healthcare professionals are increasingly focused on comprehensive testing standards to manage the growing patient population that requires blood transfusions.

Regulatory Compliance and Safety Standards: Regulatory bodies are enforcing stronger rules to assure the safety and efficacy of blood transfusion procedures. These requirements require comprehensive diagnostic testing which increases the demand for high-quality reagents, kits, and instruments. As compliance requirements become increasingly stringent, healthcare facilities invest in dependable diagnostic solutions to achieve these safety standards.

Global Blood Transfusion Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global blood transfusion diagnostics market:

North America:

The North American leads the blood transfusion diagnostics market due to its advanced healthcare infrastructure and high healthcare spending. Canada and Mexico both contribute significantly to market growth to a lesser level. The American Cancer Society estimates that 1.9 million new cancer cases will be identified in the United States in 2021 with many requiring blood transfusions during treatment.

According to the American Red Cross, the United States requires roughly 29,000 units of red blood cells every day. Another important driver is the increasing number of surgical procedures. The aging population also helps to drive market growth as older people are more likely to require blood transfusions. According to the United States Census Bureau, by 2030, all baby boomers will be over the age of 65, bringing the total elder population to 73 million people.

Blood transfusion diagnostics have improved in terms of safety and efficiency thanks to technological breakthroughs such as nucleic acid amplification testing (NAT). The FDA states that NAT can detect HIV 10 to 14 days sooner than previous antibody tests, considerably lowering the risk of transfusion-transmitted infections.

Asia Pacific:

The Asia Pacific blood transfusion diagnostics market is expanding rapidly with the area emerging as the fastest-growing market internationally. This acceleration is mostly due to the increasing population, rising prevalence of chronic diseases, and improved healthcare infrastructure in nations such as China and India. According to the World Health Organization, the prevalence of diabetes in the Western Pacific region, which includes many Asian countries, is anticipated to rise by 57%, from 131 million in 2021 to 206 million in 2045.

This growth in chronic diseases frequently needs blood transfusions, increasing the demand for diagnostic technologies. Furthermore, the growing number of surgical procedures in the region supports market expansion. According to World Bank data, current health expenditure per capita in East Asia and the Pacific has increased by 75%, from $571 in 2010 to $1,001 in 2019. This increased funding has resulted in better-equipped hospitals and blood banks accelerating the implementation of modern blood transfusion testing technology.

Furthermore, government attempts to improve blood safety are driving market expansion. For example, the National AIDS Control Organization (NACO) in India reported that HIV screening of given blood units has increased from 80% in 2007 to 100% in subsequent years, demonstrating the growing importance of blood safety procedures.

Global Blood Transfusion Diagnostics Market: Segmentation Analysis

The Global Blood Transfusion Diagnostics Market is segmented based on Component, Application, End-User, and Geography.

Blood Transfusion Diagnostics Market, By Component

• Reagents & Kits
• Instruments
• Software & Services

Based on the Component, the Global Blood Transfusion Diagnostics Market is bifurcated into Reagents & Kits, Instruments, and Software & Services. Reagents & Kits dominate the global blood transfusion diagnostics market due to their essential role in conducting blood typing, disease screening, and cross-matching tests. These consumables are in constant demand as they are critical for every transfusion procedure regardless of the equipment used. Reagents & kits are used across various healthcare settings including hospitals, blood banks, and diagnostic laboratories ensuring consistent market demand. Additionally, the frequent use and shorter shelf life of reagents and kits drive repeat purchases further boosting their market dominance.

Blood Transfusion Diagnostics Market, By Application

• Blood Grouping
• Disease Screening

Based on the Application, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Grouping and Disease Screening. In the global blood transfusion diagnostics market, disease screening is the dominant application. This is primarily driven by the critical need to ensure the safety of blood transfusions by screening for infectious diseases such as HIV, hepatitis, syphilis, and others. With stringent safety regulations in place, disease screening has become a priority to prevent the transmission of infections through blood transfusions. Additionally, advancements in testing technologies such as nucleic acid testing (NAT) have enhanced the ability to detect pathogens with greater accuracy and speed.

Blood Transfusion Diagnostics Market, By End-User

• Blood Banks
• Hospitals
• Diagnostic Laboratories

Based on the End-User, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Banks, Hospitals, and Diagnostic Laboratories. Hospitals are the dominant end-user in the blood transfusion diagnostics market due to their critical role in administering blood transfusions. Hospitals handle a wide range of medical conditions including surgeries, trauma care, and chronic diseases where blood transfusions are frequently required. As a result, they maintain a constant demand for accurate and timely blood transfusion diagnostics to ensure patient safety and effective treatment outcomes. Additionally, hospitals have integrated diagnostic facilities and blood banks that allow for seamless testing, cross-matching, and transfusion services.

Blood Transfusion Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Blood Transfusion Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global blood transfusion diagnostics market primarily due to the well-established healthcare infrastructure and the high demand for advanced diagnostic technologies. The region's strong presence of major diagnostic companies such as Abbott Laboratories and Ortho Clinical Diagnostics, drives innovation and adoption of cutting-edge blood testing methods. Additionally, North America has a robust blood donation system and stringent regulations ensuring the safety of transfusions which boosts demand for accurate diagnostic tools. The increasing prevalence of chronic diseases, surgical procedures, and trauma cases further elevates the need for reliable blood transfusion diagnostics.

Key Players

The "Global Blood Transfusion Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Grifols, Bio-Rad Laboratories, Immucor, Ortho Clinical Diagnostics, Quotient Limited, Roche Diagnostics, Haemonetics, Terumo BCT, and Beckman Coulter.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Transfusion Diagnostics Market Key Developments

• In November 2023, Grifols announced the Grifols sCD38 solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients.
• In March 2022, Mylab Discovery Solutions Pvt. Ltd. launched the NATSpert ID tripleH detection kit, san RT-PCR test that detects infection in given blood.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY COMPONENT

• 5.1 Overview
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Software & Services

6 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY APPLICATIONS

• 6.1 Overview
• 6.2 Blood Grouping
• 6.3 Disease Screening

7 BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

• 7.1 Blood Banks
• 7.2 Hospitals
• 7.3 Diagnostic Laboratories

8 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Ortho clinical Diagnostics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 DiaSorin S.p. A
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Grifols
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 S.A., F.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Hoffmann-La Roche Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bio-Rad Laboratories
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Siemens Healthcare Private Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 Thermo Fisher Scientific Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 Beckman Coulter, Inc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1.1 Related Research